| Daniel Libke, MD | |
|
385 Moraga Ave, Piedmont, CA 94611-3927 | |
| (510) 410-1545 | |
| Not Available |
| Full Name | Daniel Libke |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 385 Moraga Ave, Piedmont, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154460517 | NPI | - | NPPES |
| A39313 | Other | CA | MEDICAL DOCTOR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A39313 (California) | Primary |
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
E. coli bacteria that have developed resistance to antibiotics will probably still be around even if we stop using antibiotics, as these strains have the same good chance as other bacteria of continuing to colonise the gut, according to a thesis at the Sahlgrenska Academy.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
More than one in 10 people who binge drinks gets behind the wheel of a car during or just after their binge. Of those who binge and drive afterward, more than half had consumed their liquor in a bar, restaurant or club.
Chicago Tribune: "Target Corp., renewing its push into retail medicine, will open eight new clinics in the Chicago area and Palm Beach, Fla., giving a boost to a form of health care delivery that has seen slower growth amid the economic downturn. The Minneapolis-based retail giant launched its first health clinic four years ago but has not been as aggressive as rivals CVS/Caremark Corp. and Walgreen Co., which have opened several hundred clinics in recent years.
Gilead Sciences, Inc. today announced that it has filed a lawsuit in U.S. District Court in New Jersey against Lupin Limited for infringement against Gilead's patents for Ranexa® (ranolazine extended-release tablets). The lawsuit is based on an Abbreviated New Drug Application filed by Lupin, which seeks approval to manufacture and market a generic version of Ranexa before the expiration of Gilead's Ranexa patents.
› Verified 6 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
E. coli bacteria that have developed resistance to antibiotics will probably still be around even if we stop using antibiotics, as these strains have the same good chance as other bacteria of continuing to colonise the gut, according to a thesis at the Sahlgrenska Academy.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
More than one in 10 people who binge drinks gets behind the wheel of a car during or just after their binge. Of those who binge and drive afterward, more than half had consumed their liquor in a bar, restaurant or club.
Chicago Tribune: "Target Corp., renewing its push into retail medicine, will open eight new clinics in the Chicago area and Palm Beach, Fla., giving a boost to a form of health care delivery that has seen slower growth amid the economic downturn. The Minneapolis-based retail giant launched its first health clinic four years ago but has not been as aggressive as rivals CVS/Caremark Corp. and Walgreen Co., which have opened several hundred clinics in recent years.
Gilead Sciences, Inc. today announced that it has filed a lawsuit in U.S. District Court in New Jersey against Lupin Limited for infringement against Gilead's patents for Ranexa® (ranolazine extended-release tablets). The lawsuit is based on an Abbreviated New Drug Application filed by Lupin, which seeks approval to manufacture and market a generic version of Ranexa before the expiration of Gilead's Ranexa patents.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Libke, MD 2100 Powell St Ste 900, Cep-medamerica Attn. Berta Avila, Emeryville, CA 94608-1844 Ph: (510) 350-2664 | Daniel Libke, MD 385 Moraga Ave, Piedmont, CA 94611-3927 Ph: (510) 410-1545 |
News Archive
E. coli bacteria that have developed resistance to antibiotics will probably still be around even if we stop using antibiotics, as these strains have the same good chance as other bacteria of continuing to colonise the gut, according to a thesis at the Sahlgrenska Academy.
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
More than one in 10 people who binge drinks gets behind the wheel of a car during or just after their binge. Of those who binge and drive afterward, more than half had consumed their liquor in a bar, restaurant or club.
Chicago Tribune: "Target Corp., renewing its push into retail medicine, will open eight new clinics in the Chicago area and Palm Beach, Fla., giving a boost to a form of health care delivery that has seen slower growth amid the economic downturn. The Minneapolis-based retail giant launched its first health clinic four years ago but has not been as aggressive as rivals CVS/Caremark Corp. and Walgreen Co., which have opened several hundred clinics in recent years.
Gilead Sciences, Inc. today announced that it has filed a lawsuit in U.S. District Court in New Jersey against Lupin Limited for infringement against Gilead's patents for Ranexa® (ranolazine extended-release tablets). The lawsuit is based on an Abbreviated New Drug Application filed by Lupin, which seeks approval to manufacture and market a generic version of Ranexa before the expiration of Gilead's Ranexa patents.
› Verified 6 days ago